Evidence map›Paper›PMID 41901307›Full record

ArticlePharmaceuticals (Basel, Switzerland)2026

Physiologically-Based Pharmacokinetics of Ribociclib Drug-Drug Interactions and Organ Impairment Pharmacokinetics in Early Breast Cancer.

Yan Ji, Felix Huth, Craig Wang, Hilmar Schiller, Francois Pierre Combes, John Crown, Peter A Fasching, Juan Pablo Zarate, Michael Untch

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yan JiNovartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.ORCID 0000-0001-9569-0574
Felix HuthNovartis Pharma AG, CH 4056 Basel, Switzerland.ORCID 0000-0002-7121-4394
Craig WangNovartis Pharma AG, CH 4056 Basel, Switzerland.
Hilmar SchillerNovartis Pharma AG, CH 4056 Basel, Switzerland.ORCID 0000-0002-1026-3985
Francois Pierre CombesNovartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.
John CrownDepartment of Medical Oncology, St Vincent's University Hospital, D04 T6F4 Dublin, Ireland.
Peter A FaschingComprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, 91054 Erlangen, Germany.ORCID 0000-0003-4885-8471
Juan Pablo ZarateNovartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.
Michael UntchInterdisciplinary Breast Cancer Center, Helios Klinikum Berlin-Buch, 13125 Berlin, Germany.

Funding

Novartis Pharmaceuticals N/A
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CYP3A4drug–drug interactionearly breast cancerhepatic impairmentrenal impairmentribociclib

Identifiers

PMID41901307
PMCPMC13029677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.